Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

Rhea-AI Summary

Veracyte, Inc (NASDAQ: VCYT) will release its Q2 2021 financial results on November 9, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Investors can join via a toll-free number or through a live webcast. Veracyte specializes in diagnostics, leveraging genomic science to enhance cancer diagnosis and treatment decisions, helping patients avoid unnecessary procedures. The company continues to develop tests across various cancers.

Positive

• Scheduled release of Q2 2021 financial results, indicating transparency.
• Host of a conference call provides opportunity for investor engagement.
• Ongoing development of diagnostic tests enhances potential market growth.

Negative

• None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Tuesday, November 9. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/3rcxuu6u. A webcast replay will be available following conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call can be accessed as follows:

		U.S./Canada participant dial-in number (toll-free):		(855) 541-0980
		International participant dial-in number:		(970) 315-0440
		Conference I.D.:		9065288

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20211012006039/en/

Investor and Media Contact:

Tracy Morris

Vice President of Corporate Communications

& Investor Relations

650-380-4413

tracy.morris@veracyte.com

Source: Veracyte, Inc.

FAQ

When will Veracyte report its second quarter 2021 earnings?

Veracyte will report its Q2 2021 earnings on November 9, 2021.

What time is the Veracyte Q2 2021 earnings call?

The earnings call is scheduled for 4:30 p.m. Eastern Time on November 9, 2021.

How can I access the Veracyte earnings call?

You can access the earnings call via a toll-free number or through a live webcast on Veracyte's website.

What does Veracyte specialize in?

Veracyte specializes in diagnostic tests that leverage genomic science to improve cancer diagnosis and treatment.